Dr Ryan O’Hare Doig, Head, Spinal Cord injury Research (SAHMRI)
Neil Sachse Centre for Spinal Cord Research (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA
Dr. Ryan O’Hare Doig’s early research career has focused on understanding the pathophysiology of secondary degeneration following neurotrauma to the central nervous system (CNS). He uses innovative analytical techniques to demonstrate biochemical, molecular and gross anatomical changes that occur following CNS injury. Dr. O’Hare Doig has developed and optimised a combinatorial treatment strategy incorporating pharmacotherapeutics for the treatment of CNS injury. Ryan’s combinatorial strategy has been assessed in a clinically relevant model of spinal cord injury (SCI), demonstrating significant functional recovery and tissue sparing, crucial for the translation of his research into clinical trials.
In 2017, Ryan joined the South Australian Health & Medical Research Institute (SAHMRI) and the Neil Sachse Centre for Spinal Cord Research, to provide his expertise in SCI and other neurotrauma models. Dr. O’Hare Doig’s lab looks to help develop new techniques to provide a more accurate diagnosis and prognosis of SCI, and to identify potential treatment strategies in a clinical setting.
-
Behavioural science in cancer screening, control and communication
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
